Promotion of Thrombopoiesis by rhIL-11 in Normal and Myelosuppressed Mice
- Author:
Conglin ZUO
1
,
2
;
Mingbo XU
;
Yongbo WANG
;
Hui YI
;
Yuxia FENG
;
Tao LI
;
Xiuzhen LIU
;
Xiangdong HUANG
Author Information
1. Beijing Shuanglu Biopharmaceutical Co Ltd. and Beijing Shuanglu Institute of Medicinal Biotechnology, Beijing 100041, China
2. Beijing Zhaoyan New Drug Research Center, Beijing 100850, China.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2000;8(1):24-30
- CountryChina
- Language:Chinese
-
Abstract:
Hematological effects of rhIL-11 on normal and myelosuppressed male BALB/c mice were observed. Mice were subcutaneously injected with rhIL-11 for 7 consecutive days, at the dose of 200 or 400 micro g/kg per day, peripheral blood platelet counts were moderately elevated on 5 days after administration and returned to base level within 4 days after discontinuation of injection. In myelosuppressed mice, treatment with rhIL-11 significantly ameliorated the degree of thrombocytopenia, the recovery of thrombocytopenia was also significantly accelerated at the dose range of 100 - 400 micro g/kg per day, and blood platelet counts reached pre-irradiated level after 13 - 15 days of treatment. The magnitudes of platelet count elevation were similar among groups of 100, 200 and 400 micro g/kg per day, although recovery appeared earlier in group of 400 micro g/kg per day. Significant increases in CFU-Meg were observed both in normal and myelosuppressed mice. Our results suggest that rhIL-11 promotes the increase of peripheral blood platelets both in normal and myelosuppressed mice, and can be used as a potential therapeutic agent for thrombocytopenia induced by chemotherapy.
